Avacta Group Announces 2024 Annual Report and Revised AGM Date

Avacta Group plc ( (GB:AVCT) ) has provided an update.

Avacta Group plc has announced the availability of its Annual Report and Accounts for 2024 and a revised date for its Annual General Meeting (AGM), now scheduled for July 2, 2025. The AGM will be held at Peel Hunt LLP in London, with limited capacity for attendees. Shareholders are encouraged to pre-register to attend, and a business update will be provided post-AGM, accessible online for those unable to attend. This announcement reflects Avacta’s commitment to transparency and stakeholder engagement, ensuring shareholders are informed and involved in the company’s developments.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

More about Avacta Group plc

Avacta Therapeutics is a clinical-stage life sciences company focused on developing innovative oncology drugs. Their proprietary pre|CISION® platform utilizes a tumor-specific protease to deliver potent cancer therapies directly to tumor sites, minimizing damage to normal tissues. The company’s pipeline includes peptide drug conjugates and Affimer® drug conjugates, offering advantages over traditional treatments.

Average Trading Volume: 1,711,109

Technical Sentiment Signal: Sell

Current Market Cap: £125.6M

For a thorough assessment of AVCT stock, go to TipRanks’ Stock Analysis page.